RetinalGenix Technologies Inc.

RetinalGenix Technologies Inc. develops medical technologies focused on screening, monitoring, and addressing ocular and systemic health conditions. Its business comprises four strategic pillars: genetic testing, retinal imaging platforms, an anonymized patient informational database, and pharmaceutical therapies. The company’s pipeline includes direct-to-consumer oral swab pharmacogenetic testing kits through its DNA/GPS subsidiary, the portable RetinalCam monitoring device, the RECAD AI database combining genetic and optical imaging data, and repurposed pharmaceutical candidates RTG-2023 and RTG-2024. Its offerings serve individual patients, physicians, and optical healthcare providers.

The company operates in the United States and maintains its principal executive office in Apollo Beach, Florida. Its operational model relies on collaborations with third-party medical device developers, clinical research organizations, optical engineering firms, and specialized laboratories rather than maintaining an extensive standalone operational footprint. RetinalGenix does not report operating any commercial retail stores.

Summary of the business section of RetinalGenix Technologies's latest annual report, written by StockData.

“has been in practice for the past 39 years in the Tampa Bay Area, developing one of the first laser refractive centers in SE and 3 ambulatory surgery centers in addition to 6 offices in four counties with 94 employees.”